RiverVest Venture Partners Co-leads $86 million Series A Financing for St. Louis-founded Startup Tioma. “This is a fantastic example of what St. Louis-based innovation, talent and resources can do to build biopharma companies that will make a difference,” said John McKearn, RiverVest managing director and Tioma board chairman. Also in this issue: RiverVest’s Fund II […]

Nancy Hong Joins RiverVest. “Nancy has a great history identifying successful investments,” said RiverVest Managing Director and co-founder Jay Schmelter. “She brings both scientific and transactional expertise and is well respected for her opinions and views on the venture industry. We’re excited to have her join the team.”   Also in this issue: RiverVest’s Fund […]

Download PDF

Spring 2013: RiverVest startup brings proven drug back to clinic for promising new application What if you could create a biotech startup focused on treating rare diseases, with clinical-stage drug candidates already in hand, and high odds of success in clinical trials?

Spring 2012: RiverVest closes on four deals, exceeds industry benchmarks RiverVest Venture Partners’ hands-on investment strategy netted big returns for its Fund I and II investors in 2011: the sale of two biopharmaceutical and two medical device companies, worth more than $1 billion.

Winter 2010: RiverVest co-leads $38.5 million Series B financing to advance breakthrough treatment for ear disorders Otonomy, Inc. is on the verge of revolutionizing the way doctors treat hearing and balance disorders. “The ear is one of the last great frontiers of pharmaceutical science,” says Jay Lichter, Ph.D., co-founder of Otonomy.

Spring 2009:  RiverVest invests in Mpex Pharmaceuticals Series D financing Mpex Pharmaceiticals will soon complete patient enrollment for two Phase II clinical trials for its proprietary MP-376 inhaled antibiotic formulation aided by a $27.5 million capital infusion led by Investor Growth Capital.

Spring 2008:  RiverVest founds and co-leads Excaliard with $15.5 million investment to fund fibrotic disease treatment RiverVest Venture Partners, in an oversubscribed syndication with Alta Partners and ProQuest Investments, closed in November on a $15.5 million Series A financing of Excaliard Pharmaceuticals.

Spring 2007:  IDev Technologies: RiverVest leads investment in promising treatment for peripheral artery disease RiverVest Venture Partners recently led a $19 million Series B financing round for IDev Technologies, Inc., an emerging leader in the treatment of peripheral artery disease (PAD) through the development and marketing of the SUPERA stent system. Joining RiverVest in the Series […]

Summer 2005: Centerre and RiverVest team up A willingness to be opportunistic was the initial ingredient in bringing RiverVest and Centerre Healthcare together. Centerre was getting started in a nearby office when their business plan landed on RiverVest Managing Director Tom Melzer’s desk. “My first reaction was that we don’t do healthcare services,” says Melzer.